Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amylyx pharmaceuticals inc - AMLX

AMLX

Close Chg Chg %
30.14 -0.65 -2.16%

Closed Market

29.49

-0.65 (2.16%)

Volume: 1.29M

Last Updated:

Sep 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: amylyx pharmaceuticals inc - AMLX

AMLX Key Data

Open

$30.28

 Day Range

29.47 - 30.70

52 Week Range

10.83 - 41.13

 Market Cap

$3.84B

Shares Outstanding

125.51M

 Public Float

106.26M

Beta

-0.12

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.43

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.71M

  

AMLX Performance

1 Week
 
 -7.00%
 
1 Month
 
 -13.24%
 
3 Months
 
 69.42%
 
1 Year
 
 107.58%
 
5 Years
 
 N/A
 

AMLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About amylyx pharmaceuticals inc - AMLX

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

AMLX At a Glance

Amylyx Pharmaceuticals, Inc.
55 Cambridge Parkway
Cambridge, Massachusetts 02142
Phone 1-617-682-0917 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -144,735,000.00
Sector Health Technology Employees 136
Fiscal Year-end 12 / 2026
View SEC Filings

AMLX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 4.348
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -5.442
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.007

AMLX Efficiency

Revenue/Employee N/A
Income Per Employee -1,064,227.941
Receivables Turnover N/A
Total Asset Turnover N/A

AMLX Liquidity

Current Ratio 14.266
Quick Ratio 14.266
Cash Ratio 13.971

AMLX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -54.854
Return on Equity -61.586
Return on Total Capital -46.506
Return on Invested Capital -60.917

AMLX Capital Structure

Total Debt to Total Equity 1.951
Total Debt to Total Capital 1.914
Total Debt to Total Assets 1.783
Long-Term Debt to Equity 1.539
Long-Term Debt to Total Capital 1.51
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amylyx Pharmaceuticals Inc - AMLX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 22.23M 380.79M 87.37M
Sales Growth
+7,700.00% +1,612.94% -77.06% -100.00%
Cost of Goods Sold (COGS) incl D&A
3.48M 26.53M 125.54M 525.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
487.00K 1.09M 904.00K 525.00K
Depreciation
487.00K 1.09M 904.00K 525.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+6,592.31% +662.33% +373.21% -99.58%
Gross Income
18.75M 354.26M (38.17M) (525.00K)
Gross Income Growth
+7,947.21% +1,789.37% -110.77% +98.62%
Gross Profit Margin
- +84.35% +93.03% -43.68%
2022 2023 2024 2025 5-year trend
SG&A Expense
220.09M 315.45M 217.51M 152.77M
Research & Development
93.45M 127.10M 103.18M 89.88M
Other SG&A
126.64M 188.36M 114.33M 62.89M
SGA Growth
+165.42% +43.33% -31.05% -29.77%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 59.05M
-
EBIT after Unusual Expense
(201.34M) 38.80M (314.73M) (153.29M)
Non Operating Income/Expense
3.74M 15.49M 12.60M 8.60M
Non-Operating Interest Income
4.29M 16.16M 13.81M 9.30M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(197.60M) 54.30M (302.14M) (144.69M)
Pretax Income Growth
-124.72% +127.48% -656.45% +52.11%
Pretax Margin
- -888.89% +14.26% -345.81%
Income Tax
774.00K 5.03M (393.00K) 46.00K
Income Tax - Current - Domestic
- 4.06M 153.00K 46.00K
Income Tax - Current - Foreign
- 774.00K 1.19M (770.00K)
Income Tax - Deferred - Domestic
- - (224.00K) 224.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(198.38M) 49.27M (301.74M) (144.74M)
Minority Interest Expense
- - - -
-
Net Income
(198.38M) 49.27M (301.74M) (144.74M)
Net Income Growth
-125.60% +124.84% -712.42% +52.03%
Net Margin Growth
- -892.38% +12.94% -345.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(198.38M) 49.27M (301.74M) (144.74M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(198.38M) 49.27M (301.74M) (144.74M)
EPS (Basic)
-2.9825 0.7328 -4.4281 -1.5305
EPS (Basic) Growth
-96.27% +124.57% -704.27% +65.44%
Basic Shares Outstanding
66.51M 67.23M 68.14M 94.57M
EPS (Diluted)
-2.9825 0.704 -4.4281 -1.5305
EPS (Diluted) Growth
-96.27% +123.60% -728.99% +65.44%
Diluted Shares Outstanding
66.51M 69.99M 68.14M 94.57M
EBITDA
(200.85M) 39.89M (254.77M) (152.77M)
EBITDA Growth
-143.06% +119.86% -738.69% +40.04%
EBITDA Margin
- -903.53% +10.48% -291.60%

Snapshot

Average Recommendation BUY Average Target Price 42.182
Number of Ratings 12 Current Quarters Estimate -0.383
FY Report Date 09 / 2026 Current Year's Estimate -1.507
Last Quarter’s Earnings -0.39 Median PE on CY Estimate N/A
Year Ago Earnings -1.53 Next Fiscal Year Estimate -1.183
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 10 10
Mean Estimate -0.38 -0.37 -1.51 -1.18
High Estimates -0.33 -0.26 -1.37 0.70
Low Estimate -0.43 -0.46 -1.60 -1.70
Coefficient of Variance -8.64 -14.94 -5.26 -57.84

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 1 1 1
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Amylyx Pharmaceuticals Inc - AMLX

Date Name Shares Transaction Value
Sep 15, 2026 James M. Frates Chief Financial Officer 234,667 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.27 per share 7,572,704.09
Sep 15, 2026 James M. Frates Chief Financial Officer 233,625 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.23 per share 7,763,358.75
Sep 15, 2026 Camille L. Bedrosian Chief Medical Officer 280,145 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.21 per share 9,023,470.45
Sep 15, 2026 Camille L. Bedrosian Chief Medical Officer 278,064 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.09 per share 9,201,137.76
Sep 15, 2026 Joshua B. Cohen Co-Chief Executive Officer; Director 3,614,042 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.16 per share 116,227,590.72
Sep 15, 2026 Joshua B. Cohen Co-Chief Executive Officer; Director 3,613,123 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.15 per share 119,775,027.45
Sep 15, 2026 Justin Klee Co-Chief Executive Officer; Director 3,614,495 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.13 per share 116,133,724.35
Sep 15, 2026 Justin Klee Co-Chief Executive Officer; Director 3,613,056 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.16 per share 119,808,936.96
Sep 15, 2026 Gina M. Mazzariello Chief Legal Officer 190,849 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.46 per share 6,194,958.54
Sep 15, 2026 Gina M. Mazzariello Chief Legal Officer 190,838 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.34 per share 6,362,538.92
May 27, 2026 Karen Mindy Firestone Director 66,900 Open market or private purchase of non-derivative security Non-derivative transaction at $13.51 per share 903,819.00
Mar 10, 2026 James M. Frates Chief Financial Officer 143,985 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Amylyx Pharmaceuticals Inc in the News